Posters from ICAAC 2010

• Double-Blind, Placebo-Controlled Phase I study of PT1.2, a Novel Anti-bacterial Protein (SASP delivery vector)

Posters from ICAAC 2009

• SASP: Activity Against Staphylococcus aureus Cells Grown Under Varied Growth Conditions

Posters from ECCMID 2009

• A Novel Antibacterial Protein which Shows Rapid Bactericidal Activity Against MRSA in the Presence of Other Antibiotics
• SASP: A Novel Antibacterial Protein with Potential to Limit the Spread of Antibiotic Resistance
  

Posters from ICAAC 2008

• Low Propensity for S. aureus to Develop Resistance to SASP or its Delivery Vector

Posters from ECCMID 2008

• SASP: Rapid Bactericidal Activity against USA strains of Methicillin Resistant Staphylococcus aureus (MRSA)
• The Efficacy of SASP Targeted to Methicillin Resistant Staphylococcus aureus (MRSA) in Mixed Staphylococcal Cultures

Posters from ICAAC 2007

• SASP: A Novel Antibacterial DNA Binding Protein and its Targeted Delivery for Staphylococcus aureus
• SASP: Rapid Bactericidal Activity against MRSA and Stationary Phase Staphylococcus aureus
• SASP: Kill Kinetics against Diverse Antibiotic Resistant Staphylococcus aureus
  
  

Papers

SASP gene delivery: A novel antibacterial approach
Fairhead H.
Drug News & Perspective 2009, 22(4):197

Antibiotic resistance is a global problem, and with bacteria having developed resistance to all approved antibacterial agents there is a growing need for innovative solutions. Phico Therapeutics has developed a new class of antibacterial agent, a platform technology called SASPject™. SASPject™ comprises modified, disabled bacterial viruses (bacteriophages) injecting a gene encoding an antibacterial protein, SASP, into target bacteria. SASP, or Small, Acid-soluble Spore Protein(s), inactivate bacterial DNA in a non-sequence-specific manner so their activity is unaffected by DNA mutations. Selected pathogens can be targeted, avoiding the normal flora. A Staphylococcus aureus-targeted SASPject™, PT1.2, developed for the nasal decolonization of S. aureus, including methicillin-resistant (MRSA) strains, is expected to complete phase I in 2009. SASPject™ PT1.2 shows good in vitro activity against a wide range of diverse clinical S. aureus isolates, including MRSA strains. A systemic SASPject™ PT1.2, and SASPjects targeted against Clostridium difficile and multidrug-resistant Gram-negative organisms are in development. The SASPject™ technology could represent a new paradigm in antibacterial therapeutics.

A full copy of this article can be obtained electronically here.